Advertisement

Medical Oncology

, 36:68 | Cite as

Hypofractionated radiotherapy combined with cetuximab in vulnerable elderly patients with locally advanced head and neck squamous cell carcinoma

  • Francesca De FeliceEmail author
  • Luigia Vetrone
  • Nadia Bulzonetti
  • Rossella Caiazzo
  • Francesco Marampon
  • Daniela Musio
  • Vincenzo Tombolini
Original Paper
  • 20 Downloads

Abstract

This study was designed to evaluate the objective response after hypofractionated radiotherapy (HFRT) combined with cetuximab (HFBRT) in vulnerable elderly patients with locally advanced head and neck squamous cell carcinoma (HNSCC). Vulnerable elderly patients with histologically proven HNSCC received HFRT (total dose 60 Gy, 3 Gy/fraction) with concurrent cetuximab (250 mg/m2 with a loading dose of 400 mg/m2 1 week before HFRT). Elderly patients were categorized as vulnerable based on mini-cog test and adult comorbidity evaluation-27 score. All patients completed the programmed HFRT and two patients received the planned cetuximab infusion. Severe acute toxicity, observed in four patients, was gastrointestinal (oral mucositis in four cases; nausea/vomiting in one case) and dermatological (acneiform eruption in three cases; radiation dermatitis in one case). Three serious adverse events were recorded in three out of six patients Overall, three patients had a partial response and three patients had progression disease 3 months after the end of the treatment. No complete response was observed. HFBRT seems to be not a safer alternative approach for vulnerable elderly patients with locally advanced HNSCC. Further prospective trials are needed to define better tumor control with less incidence of toxic effects in vulnerable elderly HNSCC patients.

Keywords

Elderly Older Hypofractionated Radiation therapy Cetuximab Head and neck Squamous cell carcinoma 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    National Comprehensive Cancer Network (NCCN). Guidelines head and neck cancers, version 2.2018. http://www.nccn.org. Accessed 27 Dec 2018.
  2. 2.
    De Felice F, Musio D, Tombolini V. Osteoradionecrosis and intensity modulated radiation therapy: an overview. Crit Rev Oncol Hematol. 2016;107:39–43.CrossRefGoogle Scholar
  3. 3.
    De Felice F, Musio D, Terenzi V, Valentini V, Cassoni A, Tombolini M, De Vincentiis M, Tombolini V. Treatment improvement and better patient care: which is the most important one in oral cavity cancer? Radiat Oncol. 2014;9:263.CrossRefGoogle Scholar
  4. 4.
    De Felice F, de Vincentiis M, Luzzi V, Magliulo G, Tombolini M, Ruoppolo G, Polimeni A. Late radiation-associated dysphagia in head and neck cancer patients: evidence, research and management. Oral Oncol. 2018;77:125–30.CrossRefGoogle Scholar
  5. 5.
    Pignon JP, le Maître A, Maillard E, Bourhis J, MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92(1):4–14.CrossRefGoogle Scholar
  6. 6.
    Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567–78.CrossRefGoogle Scholar
  7. 7.
    Ries LA, Eisner MP, Kosary CL. SEER cancer statistics review, 1975-2014. 2018. Bethesda, MD: National Cancer Institute.Google Scholar
  8. 8.
    Hurria A, Dale W, Mooney M, Rowland JH, Ballman KV, Cohen HJ, Muss HB, Schilsky RL, Ferrell B, Extermann M, Schmader KE, Mohile SG, Cancer and Aging Research Group. Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendations. J Clin Oncol. 2014;32(24):2587–94.CrossRefGoogle Scholar
  9. 9.
    Borson S, Scanlan JM, Chen P, Ganguli M. The Mini-Cog as a screen for dementia: validation in a population-based sample. J Am Geriatr Soc. 2003;51(10):1451–4.CrossRefGoogle Scholar
  10. 10.
    Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004;291(20):2441–7.CrossRefGoogle Scholar
  11. 11.
    Brouwer CL, Steenbakkers RJ, Bourhis J, Budach W, Grau C, Grégoire V, van Herk M, Lee A, Maingon P, Nutting C, O’Sullivan B, Porceddu SV, Rosenthal DI, Sijtsema NM, Langendijk JA. CT-based delineation of organs at risk in the head and neck region: DAHANCA, EORTC, GORTEC, HKNPCSG, NCIC CTG, NCRI, NRG Oncology and TROG consensus guidelines. Radiother Oncol. 2015;117(1):83–90.CrossRefGoogle Scholar
  12. 12.
    Marks LB, Yorke ED, Jackson A, Ten Haken RK, Constine LS, Eisbruch A, Bentzen SM, Nam J, Deasy JO. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S10–9.CrossRefGoogle Scholar
  13. 13.
    Cancer Therapy Evaluation Program. Common terminology criteria for adverse events, version 5.0 2018. http://ctep.cancer.gov.
  14. 14.
    Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.CrossRefGoogle Scholar
  15. 15.
    Pryor DI, Porceddu SV, Burmeister BH, Guminski A, Thomson DB, Shepherdson K, Poulsen M. Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer. Radiother Oncol. 2009;90(2):172–6.CrossRefGoogle Scholar
  16. 16.
    Chan A, Teoh D, Sanghera P, Hartley A. Radiotherapy compliance is maintained with hypofractionation and concurrent cetuximab in locally advanced head and neck cancer. Radiother Oncol. 2009;93(3):654.CrossRefGoogle Scholar
  17. 17.
    Noor A, Gibb C, Boase S, Hodge JC, Krishnan S, Foreman A. Frailty in geriatric head and neck cancer: a contemporary review. Laryngoscope. 2018;128(12):E416–24.CrossRefGoogle Scholar
  18. 18.
    Choi YJ, Chung J, Shin HJ, Cho GJ, Wang SG, Lee BJ, Cho BM, Kim DW, Kim HJ, Lee WS, Joo YD, Sohn CH. Induction chemotherapy of docetaxel and cisplatin for the elderly patients with squamous cell carcinoma of the head and neck. Cancer Res Treat. 2007;39(1):1–5.CrossRefGoogle Scholar
  19. 19.
    Jang IJH, Skanthakumar T, Tan HK, Tan NC, Soo KC, Iyer NG. Elderly patients with advanced head and neck carcinoma: does aggressive treatment result in better outcomes? Otolaryngol Head Neck Surg. 2018.  https://doi.org/10.1177/0194599818815065.CrossRefPubMedGoogle Scholar
  20. 20.
    Zandberg DP, Cullen K, Bentzen SM, Goloubeva OG. Definitive radiation with concurrent cetuximab vs. radiation with or without concurrent cytotoxic chemotherapy in older patients with squamous cell carcinoma of the head and neck: analysis of the SEER-medicare linked database. Oral Oncol. 2018;86:132–40.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of RadiotherapyPoliclinico Umberto I, “Sapienza” University of RomeRomeItaly

Personalised recommendations